Readout LOUD podcast: New obesity startup, future of Teledoc

How does a startup compete with the likes of Eli Lilly and Novo Nordisk in the rapidly evolving field of weight loss drugs? And how did a major telemedicine company fall flat after its pandemic-induced rise?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field.

For more on what we cover, here’s our article on Metsera; here’s STAT’s Obesity Drug Tracker, where you can find all of the weight loss drugs in development; and here is our analysis of what went wrong at Teledoc.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].